Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL419778 | 0.81 | POLB (0.34) | POLBSMN1; SMN2 | |
| SCHEMBL8700244 | 0.79 | POLB (0.30) | POLBSMN1; SMN2 | |
| SCHEMBL424803 | 0.79 | POLB (0.33) | POLBSMN1; SMN2 | |
| SCHEMBL422862 | 0.76 | POLB (0.30) | POLBSMN1; SMN2 | |
| SCHEMBL422985 | 0.73 | POLB (0.34) | POLBSMN1; SMN2 | |
| SCHEMBL421951 | 0.71 | PKM (0.39) | POLBSMN1; SMN2 | |
| SCHEMBL421584 | 0.68 | — | — | |
| Desmethylthiamethoxam SCHEMBL8706857 | 0.67 | MAPT (0.36) | POLBSMN1; SMN2 | |
| SCHEMBL6959854 | 0.62 | — | — | |
| SCHEMBL6959860 | 0.62 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11541091-B2 | Panax plant extract and pharmaceutical composition and use thereof | SHANGHAI HUIYU BIOMEDICAL TECHNOLOGY CO., LTD. (CN) | 2023-01-03 | — | — | US | claimed |
| EP-0850231-B1 | PROCESS FOR PREPARING A 2-CHLORO-5-CHLOROMETHYL-THIAZOLE COMPOUND | SYNGENTA PARTICIPATIONS AG (CH) | 2003-04-02 | — | — | EP | claimed |
| US-6187927-B1 | REACTING 2-CHLOROALLYLFORMAMIDE WITH DEHYDRATING, HALOGENATING, AND SULFURIZING AGENTS | NOVARTIS CROP PROTECTION, INC. | 2001-02-13 | — | — | US | claimed |
| US-11541091-B2 | Panax plant extract and pharmaceutical composition and use thereof | SHANGHAI HUIYU BIOMEDICAL TECHNOLOGY CO., LTD. (CN) | 2023-01-03 | — | — | US | disclosed |
| EP-3480196-A1 | PROCESS FOR THE PREPARATION OF THIAMETHOXAM | Jiangsu Rotam Chemistry Co., Ltd (CN) | 2019-05-08 | — | — | EP | disclosed |
| US-20120022053-A1 | Oxadiazine Derivatives | SYNGENTA CROP PROTECTION, INC. (US) | 2012-01-26 | — | — | US | disclosed |
| US-7655650-B2 | Oxadiazine derivatives | Syngenta Corporation (US) | 2010-02-02 | — | — | US | disclosed |
| US-20070219188-A1 | Oxadiazine Derivatives | SYNGENTA CROP PROTECTION, INC. (US) | 2007-09-20 | — | — | US | disclosed |
| EP-0580553-B1 | Oxadiazine derivatives | SYNGENTA PARTICIPATIONS AG (CH) | 2003-11-26 | — | — | EP | disclosed |
| US-6627753-B1 | Agricultural insecticides | SYNGENTA INVESTMENT CORPORATION | 2003-09-30 | — | — | US | disclosed |
| EP-0850231-B1 | PROCESS FOR PREPARING A 2-CHLORO-5-CHLOROMETHYL-THIAZOLE COMPOUND | SYNGENTA PARTICIPATIONS AG (CH) | 2003-04-02 | — | — | EP | disclosed |
| US-6376487-B1 | SELECTIVE INSECTICIDES FOR KILLING FLIES, ROACHES, WEEVILS, AND OTHER PESTS; FOR USE ON COTTON, LEGUMES, FRUITS, CEREALS, BEANS, AND OTHER CROPS | SYNGENTA INVESTMENT CORP. | 2002-04-23 | — | — | US | disclosed |
| US-6187927-B1 | REACTING 2-CHLOROALLYLFORMAMIDE WITH DEHYDRATING, HALOGENATING, AND SULFURIZING AGENTS | NOVARTIS CROP PROTECTION, INC. | 2001-02-13 | — | — | US | disclosed |
| US-6022871-A | INSECTICIDES | NOVARTIS CORPORATION (US) | 2000-02-08 | — | — | US | disclosed |
| US-5852012-A | Oxadiazine derivatives | NOVARTIS CORPORATION (US) | 1998-12-22 | — | — | US | disclosed |
| EP-0850231-A1 | PROCESS FOR PREPARING A 2-CHLORO-5-CHLOROMETHYL-THIAZOLE COMPOUND | Novartis AG (CH) | 1998-07-01 | — | — | EP | disclosed |
| WO-1997010226-A1 | PROCESS FOR PREPARING A 2-CHLORO-5-CHLOROMETHYL-THIAZOLE COMPOUND | NOVARTIS AG (CH) | 1997-03-20 | — | — | WO | disclosed |
| EP-0580553-A2 | Oxadiazine derivatives | CIBA-GEIGY AG (CH) | 1994-01-26 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070219188-A1 | Oxadiazine Derivatives | CBR3, AOC3, AOC2 | POLB 2769/4885SMN1; SMN2 4391/4885 |
| US-20120022053-A1 | Oxadiazine Derivatives | CBR3, AOC3, AOC2 | POLB 2769/4885SMN1; SMN2 4391/4885 |
| US-11541091-B2 | Panax plant extract and pharmaceutical composition and use thereof | RXFP3, PCSK9, RXFP1 | POLB 4467/4885SMN1; SMN2 3465/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.